Data demonstrates the potential for de novo engineering of novel synthetic cytotoxic effector cells that show significant promise as 鈥渙ff the shelf鈥� cancer therapeutics
SEATTLE, April 8, 2022 (GLOBE NEWSWIRE) 鈥� 密桃视频, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo(VivoVec) and induced pluripotent stem cell (iPSC) based immunotherapies for the treatment of solid tumors and hematologic malignancies, announced today the presentation of data supporting the use of a synthetic cytokine receptor, the Rapamycin Activated Cytokine Receptor (RACR), to derive synthetic innate lymphoid cells, RACR-induced cytotoxic innate lymphoid cells (RACR-iCILs). The data will be presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, held from April 8-13, 2022.
鈥淪ome of the current limitations of cell therapies are the need for lymphodepletion, and repetitive lymphodepletion at that, in addition to the challenge of in vivo expansion,鈥� said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频. 鈥淥ur induced pluripotent stem cell platform seeks to address many of the limitations holding back cell therapy as we know it. By using a synthetic cytokine receptor that can mimic the downstream signaling of the common gamma chain cytokines essential to lymphoid cell differentiation, we are able to create a renewable starting material for scalable manufacturing of synthetic allogeneic chimeric antigen receptor cell products.鈥�
On Sunday, April 10th, Samantha O鈥橦ara, Ph.D., Principal Scientist at 密桃视频, will present a poster () titled 鈥淕eneration of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeutics.鈥� The data highlights 密桃视频鈥檚 iPSC-based cell therapy platform in which stem cells are engineered ex vivo to express 密桃视频鈥檚 RACR system and a universal adapter-specific TagCAR. The RACR system is intended to be utilized during the manufacturing process where it has the potential to deliver controlled and consistent proliferation and differentiation signals, resulting in the production of a highly pure, induced cytotoxic innate lymphoid cell product. In addition, the RACR system could enable enhanced in vivo engraftment and persistence in the absence of lymphodepleting chemotherapy. The universal adapter-specific TagCAR is designed to enable simultaneous targeting of tumor, tumor stroma, and immunosuppressive cells in the presence of a cocktail of bispecific small molecule adapters, called TumorTags.
About 密桃视频, Inc. 密桃视频, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy. 密桃视频, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies by reprogramming a patient鈥檚 immune system in vivo. Founded based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, 密桃视频鈥檚 novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer.鈥� 密桃视频 believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit鈥�.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about 密桃视频, Inc. (the 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渦s,鈥� or 鈥渙ur鈥�). The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company鈥檚 current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com